Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Round, J; Akpinar, I; Yan, C; Patel, N; van, Katwyk, S; Montgomery, C; Wald, R; Bagshaw, SM, , STARRT-AKI, Investigators.
Cost-Utility Analysis of Accelerated and Standard Strategies for Renal Replacement Therapy Initiation.
JAMA Netw Open. 2025; 8(10): e2535343 Doi: 10.1001/jamanetworkopen.2025.35343 [OPEN ACCESS]
PubMed FullText FullText_MUG

 

Study Group Mitglieder der Med Uni Graz:

Eller Philipp

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

IMPORTANCE: Little is known about the long-term costs and outcomes related to strategies for timing of initiation of kidney replacement therapy (KRT) in critically ill patients with severe acute kidney injury (AKI). OBJECTIVE: To estimate the cost-utility and cost-effectiveness of accelerated KRT initiation compared with standard KRT initiation in critically ill patients with AKI. DESIGN, SETTING, AND PARTICIPANTS: In this economic evaluation, a state-transition model was developed using data from the Standard vs Accelerated Initiation of Renal Replacement Therapy in AKI (STARRT-AKI) trial, a multicenter, multinational randomized clinical trial of critically ill patients with severe AKI conducted between October 2015 and September 2019. Trial data were linked to administrative health databases in Alberta, Canada, to estimate costs and long-term clinical outcomes. The model included 4 health states: no chronic kidney disease, severe chronic kidney disease, KRT dependent, and dead. Costs are reported in 2024 Canadian dollars. Data were analyzed from February 2022 to November 2024. EXPOSURE: Initiation of KRT. MAIN OUTCOMES AND MEASURES: The primary outcome for the economic evaluation was cost per quality-adjusted life-year (QALY) gained. The QALY is a combined measure of patient quality of life and length of life. Expected costs, QALYs, incremental cost-effectiveness ratio (ICER), and incremental net monetary benefit (INMB) were estimated on the basis of 5000 Monte Carlo simulations. RESULTS: A total of 146 patients from the STARRT-AKI trial were included in the analysis, with 73 patients (mean [SD] age, 59.67 [14.5] years; 52 men [71.3%]) randomized to receive accelerated initiation and 73 patients (mean [SD] age, 61.88 [12.9] years; 48 men [65.8%]) randomized to receive standard initiation. Standard initiation was more costly per patient than accelerated initiation (mean [SD], $251 370 [$155 801] vs $231 518 [$183 302]) but generated more QALYs (mean [SD] 7.49 [2.03] QALYs vs 6.64 [1.76] QALYs). The ICER of standard initiation compared with accelerated initiation was $23 208, with an INMB of $22 648 (95% credible interval, $15 980-$29 316) when assuming a willingness to pay per QALY of $50 000. CONCLUSIONS AND RELEVANCE: The findings of this economic evaluation suggest that standard KRT initiation may be cost-effective in a Canadian setting, but this finding was sensitive to postdischarge cost trajectories and regional variation in KRT dependence.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

Cost-Benefit Analysis - administration & dosage

Renal Replacement Therapy - economics, methods

Male - administration & dosage

Female - administration & dosage

Quality-Adjusted Life Years - administration & dosage

Middle Aged - administration & dosage

Acute Kidney Injury - therapy, economics

Aged - administration & dosage

Alberta - administration & dosage

Critical Illness - therapy, economics

Canada - administration & dosage

© Med Uni Graz • Impressum